Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 105 clinical trials
None
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide Etoposide Doxil Dexamethasone Ibrutinib Rituximab (TEDDI-R) in Primary CNS Lymphoma

(ABC) origin. Ibrutinib is an inhibitor of Bruton s tyrosine kinase (BTK) and effective for systemic DLBCL of ABC origin. We propose doing a study in which ibrutinib is combined

b-cell lymphoma
oophorectomy
rituximab
isavuconazole
anticoagulants
  • 1 views
  • 05 Dec, 2021
  • 1 location
None
A Pilot Study on Intermittent Ibrutinib in Patients With Advanced-phase Chronic Lymphocytic Leukemia (CLL)

Ibrutinib, an inhibitor of Brutons tyrosine kinase (BTK) is approved in CLL as continuous, daily administration of 420 mg orally until progression. Ibrutinib drug costs in health care are

  • 0 views
  • 05 Mar, 2021
  • 9 locations
None
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma

This phase II trial studies the side effects and how well nivolumab and ibrutinib works in treating patients with central nervous system lymphoma that has come back or does not respond to

  • 17 views
  • 04 Apr, 2021
  • 1 location
None
Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma

The purpose of this study is to test the safety of abexinostat at different doses to find out if it can work with ibrutinib to stop the cancer from growing.

b-cell lymphoma
diffuse large b-cell lymphoma
hodgkin's disease
cancer
neutrophil count
  • 22 views
  • 10 Oct, 2021
  • 7 locations
None
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid

anemia
monoclonal protein
chronic lymphocytic leukemia
acalabrutinib
monoclonal antibodies
  • 20 views
  • 08 Sep, 2021
  • 13 locations
None
Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

monoclonal protein
bone marrow procedure
g-csf
monoclonal antibodies
therapeutic regimen
  • 2 views
  • 22 Jun, 2021
  • 5 locations
None
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma

This phase I trial studies the side effects and best dose of pevonedistat when given together with ibrutinib in participants with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has

absolute neutrophil count
idelalisib
chronic lymphocytic leukemia
marginal zone lymphoma
venetoclax
  • 12 views
  • 17 Jul, 2021
  • 2 locations
None
Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma

Safety of combination of ibrutinib and radiation at various dose levels in unmethylated o6-methylguanine-DNA-methyltransferase (MGMT) glioblastoma and study of ibrutinib, temozolomide, and

methylated
MRI
temozolomide
cancer
neutrophil count
  • 93 views
  • 01 Sep, 2021
  • 1 location
None
Copanlisib With Ibrutinib for Patients With Recurrent/ Refractory Primary Central Nervous System Lymphoma (PCNSL)

The purpose of this study is to test the safety of combined use of the study drugs, copanlisib and ibrutinib, in people with PCNSL.

  • 8 views
  • 23 Jun, 2021
  • 13 locations
None
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

This is a Phase 1b/2 study to investigate the safety and effectiveness of the investigational drug, cirmtuzumab, when given in combination with ibrutinib in patients with B-cell lymphoid

anemia
monoclonal protein
cancer
neutrophil count
leukemia
  • 56 views
  • 08 Nov, 2020
  • 4 locations